Posts by: Vanessa Pataia

News

Mylotarg (gemtuzumab ozogamicin) has been approved for the first-line treatment of children, ages one month or older, who have acute myeloid leukemia (AML) positive for the CD33 protein, the U.S. ... Read more

June 11, 2020June 11, 2020

Protocol First Wins Funding for Beat AML Clinical Trial

News

Protocol First has received a funding commitment from The Leukemia & Lymphoma Society (LLS) to help advance the Beat AML Master Clinical Trial (Beat AML), which seeks to evaluate several ... Read more

May 7, 2020May 7, 2020

FDA Reviewing CC-486 as Maintenance Treatment of Adult Patients in Remission

News

The U.S. Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s application for CC-486 as a maintenance treatment for adults with acute myeloid leukemia (AML) who achieved complete remission ... Read more